KCM
FATE icon

Kingdon Capital Management’s Fate Therapeutics FATE Stock Holding History

Kingdon Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-387,294
Closed -$1.53M – 127
2017
Q3 		$1.53M Sell
387,294
-763,653
-66% -$2.6M 0.1% 101
2017
Q2 		$3.73M Sell
1,150,947
-561,011
-33% -$2.15M 0.25% 76
2017
Q1 		$7.79M Sell
1,711,958
-903,889
-35% -$3.31M 0.43% 61
2016
Q4 		$6.57M Sell
2,615,847
-212,042
-7% -$568K 0.32% 84
2016
Q3 		$8.82M Buy
2,827,889
+569,969
+25% +$1.38M 0.4% 60
2016
Q2 		$3.84M Hold
2,257,920
– – 0.21% 81
2016
Q1 		$4.06M Sell
2,257,920
-338,569
-13% -$697K 0.22% 80
2015
Q4 		$8.75M Buy
2,596,489
+194,265
+8% +$817K 0.43% 64
2015
Q3 		$12.8M Sell
2,402,224
-5,188
-0.2% -$35.4K 0.62% 47
2015
Q2 		$15.6M Buy
2,407,412
+884,137
+58% +$5.29M 0.61% 56
2015
Q1 		$7.45M Sell
1,523,275
-30,900
-2% -$153K 0.32% 88
2014
Q4 		$7.82M Buy
1,554,175
+126,500
+9% +$558K 0.34% 83
2014
Q3 		$7.28M Buy
1,427,675
+230,000
+19% +$1.33M 0.33% 79
2014
Q2 		$7.8M Buy
1,197,675
+84,200
+8% +$593K 0.3% 94
2014
Q1 		$10.5M Buy
1,113,475
+251,673
+29% +$1.94M 0.54% 61
2013
Q4 		$5.41M Buy
+861,802
New +$5.43M 0.25% 116

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kingdon Capital Management's FATE Position: Q4 2017 in Review

Kingdon Capital Management sold out of Fate Therapeutics (FATE) in Q4 2017, closing a stake of 387,294 shares — an estimated $1.53M sold.

Kingdon Capital Management first reported a position in FATE in Q4 2013 and held it in 16 quarters. The position peaked at $15.6M in Q2 2015. 78 funds tracked by Wall St. Rank hold FATE as of Q4 2017.

  • Kingdon Capital Management reported no remaining Fate Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Kingdon Capital Management sold 387,294 Fate Therapeutics shares in Q4 2017, an estimated $1.53M.
  • Kingdon Capital Management first reported a position in Fate Therapeutics in Q4 2013 and held it in 16 quarters.
  • Kingdon Capital Management's Fate Therapeutics position peaked at $15.6M in Q2 2015.
  • 78 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2017.

Based on Kingdon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.